ReviewProstate cancer and prostatic diseases2012
Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior.
Review in Prostate cancer and prostatic diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Prognostic value of C-reactive protein in patients with glioma: a meta-analysis.Biomarkers in medicine · 2024Pooled it
- Prognostic significance of C-reactive protein in patients with cervical cancer: a meta-analysis.Frontiers in oncology · 2023Pooled it
- Prognostic Role of C-Reactive Protein In Urological Cancers: A Meta-Analysis.Scientific reports · 2015Pooled it
- Prognostic role of NLR in urinary cancers: a meta-analysis.PloS one · 2014Pooled it
- NF-κB Signaling in Prostate Cancer Progression: Inflammatory Mediators, Survival Pathways, and Regulatory Axes.Cancers · 2026Review
- Dietary saturated fatty acids and prostate cancer: insights into NF-κB pathway and lipid metabolism mechanisms.Discover oncology · 2025Review
- Harvesting the Power of Green Synthesis: Gold Nanoparticles Tailored for Prostate Cancer Therapy.International journal of molecular sciences · 2024Article
- Exploiting Interdata Relationships in Prostate Cancer Proteomes: Clinical Significance of HO-1 Interactors.Antioxidants (Basel, Switzerland) · 2022Article
- TCF7L1 regulates cytokine response and neuroendocrine differentiation of prostate cancer.Oncogenesis · 2021Article
- Polyphenol-Enriched Blueberry Preparation Controls Breast Cancer Stem Cells by Targeting FOXO1 and miR-145.Molecules (Basel, Switzerland) · 2021Article
- Research Trends and Regulation of CCL5 in Prostate Cancer.OncoTargets and therapy · 2021Review
- HO-1 Interactors Involved in the Colonization of the Bone Niche: Role of ANXA2 in Prostate Cancer Progression.Biomolecules · 2020Article
- Can epigenetic and inflammatory biomarkers identify clinically aggressive prostate cancer?World journal of clinical oncology · 2020Review
- Hematogenous Dissemination of Mesenchymal Stem Cells from Endometriosis.Stem cells (Dayton, Ohio) · 2018Article
- Can routine peripheral blood counts like neutrophil-to-lymphocyte ratio be beneficial in prediagnosis of testicular cancer and its stages?Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2018Article
- A standardized herbal extract mitigates tumor inflammation and augments chemotherapy effect of docetaxel in prostate cancer.Scientific reports · 2017Article
- Low vitamin D status is associated with inflammation in patients with prostate cancer.Oncotarget · 2017Article
- Prognostic significance of lymphocyte-to-monocyte ratio and CRP in patients with nonmetastatic clear cell renal cell carcinoma: a retrospective multicenter analysis.OncoTargets and therapy · 2016Article
- Article
- Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer.SpringerPlus · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is currently estimated that inflammatory responses are linked to 15-20% of all deaths from cancer worldwide. Although many studies point to an important role of inflammation in prostate growth, the contribution of inflammation to castration-resistant prostate cancer is not completely understood. The presence of inflammatory mediators in tumor microenvironment raises the question whether genetic events that participate in cancer development and progression are responsible for the inflammatory milieu inside and surrounding tumors. Activated oncogenes, cytokines, chemokines and their receptors, sustained oxidative stress and antioxidant imbalance share the capacity to orchestrate these pro-inflammatory programs; however, the diversity of the inflammatory cell components will determine the final response in the prostate tissue. These observations give rise to the concept that early genetic events generate an inflammatory microenvironment promoting prostate cancer progression and creating a continuous loop that stimulates a more aggressive stage. It is imperative to dissect the molecular pathologic mechanism of inflammation involved in the generation of the castration-resistant phenotype in prostate cancer. Here, we present a hypothesis where molecular signaling triggered by inflammatory mediators may evolve in prostate cancer progression. Thus, treatment of chronic inflammation may represent an important therapeutic target in advanced prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.